Johnson & Johnson
Develops prescription medicines and cardiovascular, surgical, orthopaedic and vision technologies.
Something off on this page? Send us feedback.
Profile
Earns revenue through two global segments: Innovative Medicine sells prescription therapies, while MedTech supplies cardiovascular, surgical, orthopaedic and vision products. Product approvals and patent cycles shape the medicine portfolio, and Orthopaedics is slated for separation.
Develops prescription medicines through Innovative Medicine and medical technologies through MedTech for healthcare systems worldwide. The medicine portfolio spans oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic conditions; DARZALEX is its largest product franchise.
Sells electrophysiology, heart-support, circulatory-restoration and neurovascular devices, plus surgical systems, orthopaedics, ACUVUE contact lenses and TECNIS intraocular lenses. Internal research, collaborations, licensing and acquisitions replenish the portfolio, while global manufacturing and specialist distribution place products with hospitals, clinicians, wholesalers and retailers.
Results depend on clinical development, regulatory approvals, patent protection, reimbursement and product safety. Patent losses can quickly erode medicine sales, and talc litigation remains unresolved. Orthopaedics remains inside MedTech while a separation into a standalone DePuy Synthes is planned.
Company facts
Key statistics
Year to date +29.3% · Average volume (30d) 6.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Reiterate | Buy | $270 | $287 | |
| Aug 3, 2026 | Raymond James | Target | $265 | $280 | ||
| Aug 3, 2026 | Wells Fargo | Reiterate | Overweight | $272 | $282 | |
| Jul 29, 2026 | Argus Research | Target | $210 | $300 | ||
| Jul 16, 2026 | Johnson Rice | Upgrade | Outperform | Buy | $261 | $280 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026Q2 FY26 | $2.84 | $2.90 | +2.1% | $25.06B | $25.31B | +1.0% | +1.19% |
| Apr 14, 2026Q1 FY26 | $2.68 | $2.70 | +0.7% | $23.61B | $24.06B | +1.9% | −0.60% |
| Jan 21, 2026Q4 FY25 | $2.46 | $2.46 | 0.0% | $24.15B | $24.56B | +1.7% | +0.22% |
| Oct 14, 2025Q3 FY25 | $2.76 | $2.80 | +1.4% | $23.76B | $23.99B | +1.0% | +0.17% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B | $25.31B | |
| Gross profit | $14.54B | $16.12B | $16.69B | $16.60B | $17.20B | $18.50B | |
| Operating income | $6.30B | $6.81B | $7.10B | $5.59B | $6.40B | $7.17B | |
| Net income | $11.00B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B | |
| Diluted EPS | $4.54 | $2.29 | $2.12 | $2.10 | $2.14 | $2.27 | |
| Gross margin | 66.4% | 67.9% | 69.6% | 67.6% | 71.5% | 73.1% | |
| Operating margin | 28.8% | 28.7% | 29.6% | 22.8% | 26.6% | 28.3% |
Fiscal years (4-quarter sums)FY21 $93.78B · FY22 $91.15B · FY23 $85.16B · FY24 $88.82B · FY25 $94.19B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 28, 2026Cash & short-term investments $20.76B · Total debt $49.04B · Total assets $201.06B · Shareholders' equity $84.97B
Dividends
Raised for 55 straight years — most recently to $1.34 from $1.30 in May 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 25, 2026 | Aug 25 | Sep 8 | $1.34 | |
| May 26, 2026 | May 26 | Jun 9 | $1.34 | raised from $1.30 |
| Feb 24, 2026 | Feb 24 | Mar 10 | $1.30 | |
| Nov 25, 2025 | Nov 25 | Dec 9 | $1.30 | |
| Aug 26, 2025 | Aug 26 | Sep 9 | $1.30 | |
| May 27, 2025 | May 27 | Jun 10 | $1.30 | raised from $1.24 |
| Feb 18, 2025 | Feb 18 | Mar 4 | $1.24 | |
| Nov 26, 2024 | Nov 26 | Dec 10 | $1.24 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 2.41B · Float 2.41B · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 212.10M | 8.80% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 157.23M | 6.52% | 13F | Aug 13, 2026 |
| State Street Corp | 133.78M | 5.55% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 64.37M | 2.67% | 13F | Aug 13, 2026 |
| Geode Capital Management, LLC | 59.09M | 2.45% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Jennifer L. Taubert | officer: EVP, WWC. Innovative Medicine | −15,000 | $263.36 |
| Aug 13, 2026 | Joaquin Duato | director, officer: CEO and Chairman of the Board | −123,291 | $261.17 |
| Aug 6, 2026 | Elizabeth Forminard | officer: EVP, Chief Legal Officer | −15,918 | $257.00 |
| Aug 5, 2026 | Joaquin Duato | director, officer: CEO and Chairman of the Board | −48,480 | $258.15 |
| Jul 20, 2026 | Vanessa Broadhurst | officer: EVP, Global Corp Affairs | −23,054 | $251.27 |
Peers
- AbbVie
Head-to-head in immunology and hematology-oncology.
- Merck
Largest pharma rival by revenue; Keytruda contests the oncology space.
- Medtronic
#1 global MedTech; contests cardiovascular, spine, and surgical with JNJ MedTech.
- Bristol-Myers Squibb
Myeloma and hematology head-to-head; overlaps in immunology and CAR-T.
- Stryker
Orthopaedic market leader challenging DePuy Synthes across joints, trauma, and spine.
- Boston Scientific
Fast-growing MedTech rival taking EP share from JNJ’s Biosense Webster.
- Abbott
Cardiovascular and electrophysiology rival challenging JNJ’s EP market position.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Median | 34.3 | 16.8 | 4.2 | +9.4% |